drugset / Trial / NCT05720117
A Study of PYX-201 in Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2027-04-25
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PYX-201 | Other / unclassified | — | — |